Cynbiose can assess the efficacy of your therapeutics or vaccine in a translational non-human primate (NHP) model. This model is relevant to test innovative or repurposed drug candidates as well as aerosoltherapies.

Species

  • Cynomolgus macaque (Macaca fascicularis)
  • African green monkey (genus Chlorocebus)

Pathogen

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) / COVID-19 strains (Primary strain, various European D614G variants, UK variant,  South-African variant, Brazilian variant, Delta variant)
  • Infection method : intratracheal, intranasal pulverization

Type of test item

  • Vaccines
  • Antibodies, immunotherapies, antiviral candidates, small molecules
  • Combined treatments
  • Aerosoltherapies & inhaled products

Objectives

  • Efficacy assessment of vaccines or therapeutics
  • Evaluation of systemic or topical (incl nebulization) administrations

Read-outs

  • Clinical follow-up
  • Core body temperature : continuous monitoring using an implantable data logger
  • Clinical pathology : biochemistry and complete blood count with differential) in a BSL1/2/3 setting thanks to state-of-the-art biological analyzers
  • Sampling : Bronchoalveolar lavage, Nasal & nasopharyngeal swabs, blood sampling, feces
  • Immunomonitoring
  • Viral detection and quantification by RT-qPCR
  • Viral titration using  using the Median Tissue Culture Infectious Dose (TCID50) assay
  • Assessment of the host response by seroneutralization assays
  • Histopathology
  • Custom readouts & biomarkers

Scientific publications

  • African Green Monkey model of SARS-CoV-2 infection shows mild lung pathology and viral replication in the airways.
    Confais J, Toussenot M, Julien T, Ployart S, Pizzorno A, Rosa-Calatrava M, Contamin H.
    Immunotherapies & Innovations for Infectious Diseases congress, 9-10th December, 2020.

Scientific partners

  • VirPath laboratory (Claude Bernard Lyon University, INSERM, CNRS, ENS Lyon) specializing in virology and human respiratory pathologies